Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure

NCT ID: NCT05652322

Last Updated: 2025-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-07

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical study is to compare treatment regimens of loop diuretics in patients with decompensated heart failure. The main aim is to answer if early change from intravenous to oral loop diuretics is safe and effective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

prolonged intravenous loop diuretic treatment - furosemide

Group Type ACTIVE_COMPARATOR

Furosemide Injection

Intervention Type DRUG

change from intravenous to oral furosemide

Group 2

Early (48 hrs) change to oral loop diuretic - furosemide - 150% eqivalent iv dose

Group Type EXPERIMENTAL

Furosemide Pill 150% equivalent iv dose

Intervention Type DRUG

change from intravenous to oral furosemide

Group 3

Early (48 hrs) change to oral loop diuretic - furosemide - 200% eqivalent iv dose

Group Type EXPERIMENTAL

Furosemide Pill 200% equivalent iv dose

Intervention Type DRUG

change from intravenous to oral furosemide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Furosemide Pill 150% equivalent iv dose

change from intravenous to oral furosemide

Intervention Type DRUG

Furosemide Pill 200% equivalent iv dose

change from intravenous to oral furosemide

Intervention Type DRUG

Furosemide Injection

change from intravenous to oral furosemide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient hospitalized due to exacerbation of heart failure symptoms, where AHF is the main cause of hospitalization. To be included in the study, all criteria 1 to 6 must be met:

1. Fluid Retention Features:

* Described congestion above the lung fields on chest X-ray
* rales on chest auscultation
* Peripheral edema, yielding to pressure occurring within the limbs or the sacral part of the spine
* Increased pressure in the jugular veins (\>=8 cm H2O)
2. The concentration of natiuretic peptides must be assessed within 24 hours of admission to the hospital and be:

✔ NTpro-BNP \>450 pg/mL for \<55 years, 900 pg/mL for 55-75 years, and \>1800 pg/mL for \>75 years
3. Exacerbation of heart failure treated with at least 40 mg of furosemide IV. (or 20 mg torasemide equivalent)
4. Left ventricular ejection fraction \< 50% (assessed and documented in the last 12 months prior to study entry)
5. Age \>= 18 years
6. The study participant gave and signed an informed consent to participate in the study. No medical procedure related to the study was performed prior to giving informed consent.

Exclusion Criteria

* 1\. Shortness of breath caused by respiratory infection, exacerbation of bronchial asthma, COPD 2. Body temperature \> 38 C, signs of active infection requiring antibiotic therapy, sepsis, infective endocarditis 3. An episode of acute coronary syndrome, stroke or TIA within 6 months before randomization 4. Severe valvular disease requiring or in the process of qualifying for repair 5. Patients requiring dialysis (in the past, during hospitalization or in the process of qualifying for dialysis) 6. History of alcohol abuse in the last 2 years before randomization 7. Pregnancy or breastfeeding 8. Active cancer or in remission for less than 5 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jan Kochanowski University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zbigniew Siudak

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janusz Sielski, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Jan Kochanowski Univeristy in Kielce

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wojewodzki Szpital Zespolony Klinika Nefrologii

Kielce, , Poland

Site Status

Wojewódzki Szpital Zespolony OIOK

Kielce, , Poland

Site Status

Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Oddzial Kardiologii

Lodz, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Related Links

Access external resources that provide additional context or updates about the study.

https://interna.ujk.edu.pl/

Jan Kochanowski University Kielce, Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1/KCW/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sub-Q Versus IV Furosemide in Acute Heart Failure
NCT02579057 COMPLETED PHASE2/PHASE3